Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Peptide Vaccine
Recent findings from A.A. Vandenbark and co-authors highlight research in peptide vaccine
March 19th, 2008
"Therapeutic vaccination using T-cell receptor (TCR) peptides from V genes commonly expressed by potentially pathogenic T cells remains an approach of interest for treatment of multiple sclerosis (MS) and other autoimmune diseases. We developed a trivalent TCR vaccine containing complementarity determining region (CDR) 2 peptides from BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant that reliably induced high frequencies of TCR-specific T cells," scientists in the United States report. "To evaluate induction of regulatory T-cell subtypes, immunological and clinical parameters were followed in 23 treatment-naive subjects with relapsing-remitting or...
Source: Vaccine Weekly (2008-03-19)
|
